Does the media favor DTIL or ELUT?

In the previous week, Elutia had 1 more articles in the media than Precision BioSciences. MarketBeat recorded 4 mentions for Elutia and 3 mentions for Precision BioSciences. Precision BioSciences' average media sentiment score of 0.94 beat Elutia's score of 0.72 indicating that Precision BioSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precision BioSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elutia 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, ADAG or ELUT?

Elutia has higher revenue and earnings than Adagene. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adagene $7.67M 26.14 -$17.61M N/A N/A Elutia $12.46M 3.29 $53.38M $0.86 1.11

Is ADAG or ELUT more profitable?

Elutia has a net margin of 312.09% compared to Adagene's net margin of 0.00%. Company Net Margins Return on Equity Return on Assets Adagene N/A N/A N/A Elutia 312.09% N/A -53.97%

Does the media refer more to ADAG or ELUT?

In the previous week, Elutia had 1 more articles in the media than Adagene. MarketBeat recorded 4 mentions for Elutia and 3 mentions for Adagene. Adagene's average media sentiment score of 0.74 beat Elutia's score of 0.72 indicating that Adagene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adagene 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elutia 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, IPHA or ELUT?

Elutia has higher revenue and earnings than Innate Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innate Pharma $10.19M 16.59 -$55.64M N/A N/A Elutia $12.46M 3.29 $53.38M $0.86 1.11

Is IPHA or ELUT more profitable?

Elutia has a net margin of 312.09% compared to Innate Pharma's net margin of 0.00%. Company Net Margins Return on Equity Return on Assets Innate Pharma N/A N/A N/A Elutia 312.09% N/A -53.97%

Is DERM or ELUT more profitable?

Elutia has a net margin of 312.09% compared to Journey Medical's net margin of -14.82%. Elutia's return on equity of 0.00% beat Journey Medical's return on equity. Company Net Margins Return on Equity Return on Assets Journey Medical -14.82% -35.57% -10.88% Elutia 312.09% N/A -53.97%

Does the media refer more to DERM or ELUT?

In the previous week, Elutia had 1 more articles in the media than Journey Medical. MarketBeat recorded 4 mentions for Elutia and 3 mentions for Journey Medical. Journey Medical's average media sentiment score of 0.84 beat Elutia's score of 0.72 indicating that Journey Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Journey Medical 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elutia 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Elutia (ELUT) Competitors

$0.96 -0.04 (-4.25%)

Closing price 04:00 PM Eastern

Extended Trading

$0.96 +0.00 (+0.26%)

As of 06:07 PM Eastern

Compare

ELUT vs. DTIL, ADAG, IPHA, MIST, and DERM

Should you buy Elutia stock or one of its competitors? MarketBeat compares Elutia with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Elutia include Precision BioSciences (DTIL), Adagene (ADAG), Innate Pharma (IPHA), Milestone Pharmaceuticals (MIST), and Journey Medical (DERM). These companies are all part of the "pharmaceutical products" industry.

How does Elutia compare to Precision BioSciences?

Precision BioSciences (NASDAQ:DTIL) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

38.0% of Precision BioSciences shares are owned by institutional investors. Comparatively, 74.0% of Elutia shares are owned by institutional investors. 2.7% of Precision BioSciences shares are owned by insiders. Comparatively, 27.6% of Elutia shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Elutia has lower revenue, but higher earnings than Precision BioSciences. Precision BioSciences is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision BioSciences	$45.07M	4.53	-$45.72M	-$3.67	N/A
Elutia	$12.46M	3.29	$53.38M	$0.86	1.11

Precision BioSciences presently has a consensus price target of $32.25, indicating a potential upside of 307.20%. Elutia has a consensus price target of $6.00, indicating a potential upside of 527.29%. Given Elutia's higher probable upside, analysts plainly believe Elutia is more favorable than Precision BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Elutia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Precision BioSciences has a beta of 1.3, meaning that its share price is 30% more volatile than the broader market. Comparatively, Elutia has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market.

In the previous week, Elutia had 1 more articles in the media than Precision BioSciences. MarketBeat recorded 4 mentions for Elutia and 3 mentions for Precision BioSciences. Precision BioSciences' average media sentiment score of 0.94 beat Elutia's score of 0.72 indicating that Precision BioSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precision BioSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elutia	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Elutia has a net margin of 312.09% compared to Precision BioSciences' net margin of -96.73%. Elutia's return on equity of 0.00% beat Precision BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precision BioSciences	-96.73%	-85.37%	-37.34%
Elutia	312.09%	N/A	-53.97%

Summary

Elutia beats Precision BioSciences on 9 of the 16 factors compared between the two stocks.

How does Elutia compare to Adagene?

Adagene (NASDAQ:ADAG) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

Adagene presently has a consensus price target of $8.00, suggesting a potential upside of 89.13%. Elutia has a consensus price target of $6.00, suggesting a potential upside of 527.29%. Given Elutia's higher probable upside, analysts clearly believe Elutia is more favorable than Adagene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
Elutia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Adagene has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market. Comparatively, Elutia has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market.

9.5% of Adagene shares are held by institutional investors. Comparatively, 74.0% of Elutia shares are held by institutional investors. 21.2% of Adagene shares are held by company insiders. Comparatively, 27.6% of Elutia shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Elutia has a net margin of 312.09% compared to Adagene's net margin of 0.00%.

Company	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
Elutia	312.09%	N/A	-53.97%

Elutia has higher revenue and earnings than Adagene.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$7.67M	26.14	-$17.61M	N/A	N/A
Elutia	$12.46M	3.29	$53.38M	$0.86	1.11

In the previous week, Elutia had 1 more articles in the media than Adagene. MarketBeat recorded 4 mentions for Elutia and 3 mentions for Adagene. Adagene's average media sentiment score of 0.74 beat Elutia's score of 0.72 indicating that Adagene is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adagene	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elutia	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Elutia beats Adagene on 8 of the 14 factors compared between the two stocks.

How does Elutia compare to Innate Pharma?

Innate Pharma (NASDAQ:IPHA) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.

Elutia has a net margin of 312.09% compared to Innate Pharma's net margin of 0.00%.

Company	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
Elutia	312.09%	N/A	-53.97%

In the previous week, Elutia had 3 more articles in the media than Innate Pharma. MarketBeat recorded 4 mentions for Elutia and 1 mentions for Innate Pharma. Innate Pharma's average media sentiment score of 1.89 beat Elutia's score of 0.72 indicating that Innate Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Innate Pharma	Very Positive
Elutia	Positive

Innate Pharma presently has a consensus price target of $5.00, suggesting a potential upside of 177.78%. Elutia has a consensus price target of $6.00, suggesting a potential upside of 527.29%. Given Elutia's higher possible upside, analysts plainly believe Elutia is more favorable than Innate Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Elutia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Elutia has higher revenue and earnings than Innate Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$10.19M	16.59	-$55.64M	N/A	N/A
Elutia	$12.46M	3.29	$53.38M	$0.86	1.11

Innate Pharma has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market. Comparatively, Elutia has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market.

0.2% of Innate Pharma shares are held by institutional investors. Comparatively, 74.0% of Elutia shares are held by institutional investors. 31.9% of Innate Pharma shares are held by company insiders. Comparatively, 27.6% of Elutia shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Elutia beats Innate Pharma on 7 of the 13 factors compared between the two stocks.

How does Elutia compare to Milestone Pharmaceuticals?

Milestone Pharmaceuticals (NASDAQ:MIST) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

86.2% of Milestone Pharmaceuticals shares are held by institutional investors. Comparatively, 74.0% of Elutia shares are held by institutional investors. 5.0% of Milestone Pharmaceuticals shares are held by insiders. Comparatively, 27.6% of Elutia shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Elutia has a net margin of 312.09% compared to Milestone Pharmaceuticals' net margin of 0.00%. Elutia's return on equity of 0.00% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%
Elutia	312.09%	N/A	-53.97%

In the previous week, Elutia had 3 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 4 mentions for Elutia and 1 mentions for Milestone Pharmaceuticals. Milestone Pharmaceuticals' average media sentiment score of 1.89 beat Elutia's score of 0.72 indicating that Milestone Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Milestone Pharmaceuticals	Very Positive
Elutia	Positive

Milestone Pharmaceuticals has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, Elutia has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market.

Elutia has higher revenue and earnings than Milestone Pharmaceuticals. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Pharmaceuticals	$1.55M	106.83	-$63.06M	-$0.68	N/A
Elutia	$12.46M	3.29	$53.38M	$0.86	1.11

Milestone Pharmaceuticals presently has a consensus price target of $7.25, suggesting a potential upside of 445.11%. Elutia has a consensus price target of $6.00, suggesting a potential upside of 527.29%. Given Elutia's higher probable upside, analysts plainly believe Elutia is more favorable than Milestone Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50
Elutia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Elutia beats Milestone Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Elutia compare to Journey Medical?

Journey Medical (NASDAQ:DERM) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

In the previous week, Elutia had 1 more articles in the media than Journey Medical. MarketBeat recorded 4 mentions for Elutia and 3 mentions for Journey Medical. Journey Medical's average media sentiment score of 0.84 beat Elutia's score of 0.72 indicating that Journey Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Journey Medical	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elutia	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Elutia has a net margin of 312.09% compared to Journey Medical's net margin of -14.82%. Elutia's return on equity of 0.00% beat Journey Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Journey Medical	-14.82%	-35.57%	-10.88%
Elutia	312.09%	N/A	-53.97%

Journey Medical has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market. Comparatively, Elutia has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market.

7.3% of Journey Medical shares are owned by institutional investors. Comparatively, 74.0% of Elutia shares are owned by institutional investors. 14.5% of Journey Medical shares are owned by insiders. Comparatively, 27.6% of Elutia shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Elutia has lower revenue, but higher earnings than Journey Medical. Journey Medical is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Journey Medical	$64.68M	2.89	-$11.43M	-$0.37	N/A
Elutia	$12.46M	3.29	$53.38M	$0.86	1.11

Journey Medical presently has a consensus price target of $13.00, indicating a potential upside of 91.46%. Elutia has a consensus price target of $6.00, indicating a potential upside of 527.29%. Given Elutia's higher probable upside, analysts clearly believe Elutia is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Elutia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Elutia beats Journey Medical on 10 of the 16 factors compared between the two stocks.

Get Elutia News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELUT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELUT vs. The Competition

Export

Metric	Elutia	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$40.92M	$3.65B	$6.84B	$12.44B
Dividend Yield	N/A	2.22%	2.67%	6.11%
P/E Ratio	1.11	21.29	25.83	24.36
Price / Sales	3.29	313.32	541.54	96.87
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	1.47	8.71	10.98	6.49
Net Income	$53.38M	$23.87M	$3.57B	$336.61M
7 Day Performance	-4.35%	4.23%	3.06%	0.90%
1 Month Performance	-17.54%	1.71%	0.72%	-0.36%
1 Year Performance	-54.45%	69.92%	36.82%	31.26%

Elutia Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELUT Elutia	3.8156 of 5 stars	$0.96 -4.3%	$6.00 +527.3%	-52.4%	$40.92M	$12.46M	1.11	180	Short Interest Decrease Gap Up
DTIL Precision BioSciences	2.5549 of 5 stars	$6.50 +3.0%	$32.25 +396.2%	+69.5%	$167.71M	$45.07M	N/A	200	News Coverage Positive News Gap Up
ADAG Adagene	2.4154 of 5 stars	$3.53 +0.6%	$8.00 +126.6%	+115.0%	$167.27M	$7.67M	N/A	260	News Coverage Gap Down
IPHA Innate Pharma	3.0338 of 5 stars	$1.78 -0.6%	$5.00 +180.9%	-3.2%	$167.18M	$2.79M	N/A	220	Positive News Analyst Upgrade
MIST Milestone Pharmaceuticals	2.4408 of 5 stars	$1.31 +1.6%	$7.25 +453.4%	-33.3%	$163.09M	$1.78M	N/A	30	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELUT) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Elutia (ELUT) Competitors

ELUT vs. DTIL, ADAG, IPHA, MIST, and DERM

How does Elutia compare to Precision BioSciences?

Summary

How does Elutia compare to Adagene?

Summary

How does Elutia compare to Innate Pharma?

Summary

How does Elutia compare to Milestone Pharmaceuticals?

Summary

How does Elutia compare to Journey Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELUT vs. The Competition

Elutia Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Elutia (ELUT) Competitors

ELUT vs. DTIL, ADAG, IPHA, MIST, and DERM

How does Elutia compare to Precision BioSciences?

Do institutionals & insiders have more ownership in DTIL or ELUT?

Which has preferable earnings & valuation, DTIL or ELUT?

Do analysts prefer DTIL or ELUT?

Which has more risk & volatility, DTIL or ELUT?

Does the media favor DTIL or ELUT?

Is DTIL or ELUT more profitable?

Summary

How does Elutia compare to Adagene?

Do analysts recommend ADAG or ELUT?

Which has more risk and volatility, ADAG or ELUT?

Do institutionals & insiders hold more shares of ADAG or ELUT?

Is ADAG or ELUT more profitable?

Which has stronger valuation and earnings, ADAG or ELUT?

Does the media refer more to ADAG or ELUT?

Summary

How does Elutia compare to Innate Pharma?

Is IPHA or ELUT more profitable?

Does the media refer more to IPHA or ELUT?

Do analysts rate IPHA or ELUT?

Which has higher valuation and earnings, IPHA or ELUT?

Which has more volatility and risk, IPHA or ELUT?

Do institutionals & insiders have more ownership in IPHA or ELUT?

Summary

How does Elutia compare to Milestone Pharmaceuticals?

Do insiders and institutionals have more ownership in MIST or ELUT?

Is MIST or ELUT more profitable?

Does the media prefer MIST or ELUT?

Which has more risk and volatility, MIST or ELUT?

Which has stronger earnings and valuation, MIST or ELUT?

Do analysts rate MIST or ELUT?

Summary

How does Elutia compare to Journey Medical?

Does the media refer more to DERM or ELUT?

Is DERM or ELUT more profitable?

Which has more volatility & risk, DERM or ELUT?

Do insiders & institutionals have more ownership in DERM or ELUT?

Which has preferable valuation & earnings, DERM or ELUT?

Do analysts rate DERM or ELUT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELUT vs. The Competition

Elutia Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools